Kiromic Biopharma
Dr. Dahlbeck has served as our Chief Medical Officer since October 2019. He previously served as our President from January 2013 to October 2019. Dr. Dahlbeck is an expert in prostate cancer research and treatment and has served as a Radiation Oncologist for several cancer centers, including as an Adjunct Assistant Professor in Internal Medicine, Pathology, and Urology at the Texas Tech University Health Sciences Center. Dr. Dahlbeck has also patented, manufactured, and commercialized IP and has more than a decade of experience in medical and oncology commerce.
Dr. Dahlbeck earned an MD from the University of Texas Health Science Center at Houston, completed residencies in family practice and radiation oncology, and earned a PharmD degree from the University of Nebraska Medical Center, College of Pharmacy.
This person is not in any offices
Kiromic Biopharma
1 followers
Kiromic Biopharma is an immuno-oncology, target discovery, and gene editing company developing highly effective and safe tumor-specific cancer engineered immunotherapies to face and defeat multiple cancer types. They are focused on extending the benefits of immunotherapy by leveraging DIAMOND AI (Kiromic Diamond Artificial Intelligence), which is a multi-purpose computational platform that can identify new cancer immunological targets for T-Cells and B-Cells.